Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
Twist Bioscience Corp (TWST) reported that Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary, sold 412 shares of common stock on September 8, 2026 at $122.62 per share. According to the company’s disclosure, these shares were sold solely to cover tax withholding upon vesting of Restricted Stock Units, and were not discretionary trades. After this transaction, Cho directly held 73,651 shares of Twist Bioscience common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Twist Bioscience Corp (TWST) reported an insider tax-related sale by Paula Green, its SVP of Human Resources. On September 8, 2026, she sold 907 shares of common stock at $122.624 per share. According to the company, this sale was a mandatory "sell to cover" for tax withholding on vesting Restricted Stock Units and was not a discretionary trade. After the transaction, she held 117,014 shares directly.
Twist Bioscience Corp (TWST) reported that Chief Executive Officer and director Emily M. Leproust sold 2,302 shares of Common Stock on September 8, 2026 at $122.624 per share. After this sale, she directly holds 768,427 shares. The sale was required to cover tax withholding on vesting Restricted Stock Units under the company’s equity incentive plans and, according to the disclosure, did not represent a discretionary trade by her. She also holds several employee stock options with exercise prices ranging from $5.95 to $67.85, including performance stock options covering 64,950 underlying shares at a $67.85 exercise price expiring August 31, 2030.
Twist Bioscience Corp (TWST) reported that Chief Accounting Officer Robert F. Werner sold 238 shares of common stock on September 8, 2026, at $122.624 per share. According to the company’s equity incentive plan, this was a mandatory “sell to cover” transaction to satisfy tax withholding on vesting RSUs, not a discretionary trade. After the sale, Werner held 44,399 shares directly.
Twist Bioscience Corp (TWST) received a Rule 144 notice relating to planned sales of its common stock by Emily M. Leproust through Fidelity Brokerage Services LLC. The notice covers an intended sale of up to 2,302 shares of common stock, with an aggregate market value of $282,280.22 as of September 8, 2026.
The shares to be sold arise from restricted stock vesting on September 4, 2026, reported as a compensation-related distribution by the issuer. The filer also discloses multiple prior sales of Twist common stock during the past three months, and notes that the current sale includes shares to cover a tax obligation from settlement of a vested equity award.
Twist Bioscience Corp (TWST) received a Rule 144 notice relating to potential sales of its common stock by officer Paula Green. The notice covers up to 907 shares of common stock to be sold through Fidelity Brokerage Services on NASDAQ, tied to restricted stock that vested on September 4, 2026 and granted as compensation. Over the prior three months, Paula Green reported multiple open-market sales of Twist Bioscience common stock, including 26,137 shares on June 15, 2026 for proceeds of $2,134,485.95. A remark states that the planned sale includes shares to cover a tax obligation from a vested equity award distribution.
Twist Bioscience Corp (TWST) is the issuer for a planned sale of common stock under Rule 144 by officer Robert F. Werner through Fidelity Brokerage Services LLC. The notice covers a proposed sale of 238 shares of common stock, acquired via restricted stock vesting as compensation from Twist Bioscience.
The filing also lists several prior sales of Twist Bioscience common stock by Robert F. Werner during the preceding three months and notes that the planned sale includes shares to cover a tax obligation arising from settlement of a vested equity award.
Twist Bioscience Corp (TWST) received a notice that officer Dennis H. Cho plans to sell 412 shares of its common stock under Rule 144. The shares were acquired on September 4, 2026 through restricted stock vesting as compensation. The notice states the sale includes shares needed to cover a tax obligation from the vested equity award and lists multiple common‑stock sales by Cho during the prior three months.
Twist Bioscience Corp (TWST) received an updated Schedule 13G/A (Amendment No. 10) from ARK Investment Management LLC and its CEO/CIO Catherine D. Wood, reporting their beneficial ownership of the company’s common stock.
As of August 31, 2026, ARK and Catherine D. Wood report beneficial ownership of 3,385,850 shares of Twist Bioscience common stock, representing 5.11% of the outstanding class. ARK reports sole voting power over 3,228,258 shares and shared voting power over 44,747 shares. ARK also reports sole dispositive power over 3,385,850 shares. Catherine D. Wood reports shared voting power over 3,273,005 shares and shared dispositive power over 3,385,850 shares, with no sole voting or dispositive power.
Twist Bioscience Corp (TWST) is the subject of an amended Schedule 13G filing reporting a significant ownership position by FMR LLC and Abigail P. Johnson. FMR LLC reports beneficial ownership of 8,760,081.45 shares of Twist Bioscience common stock, representing 13.2% of the outstanding class.
FMR LLC reports sole dispositive power over 8,760,081.45 shares and sole voting power over 8,755,210.44 shares, with no shared voting or dispositive power. Abigail P. Johnson is reported to have sole dispositive power over the same 8,760,081.45 shares and no voting power, reflecting her control relationship to FMR LLC.
The filing notes that one or more other persons have the right to receive or direct dividends or sale proceeds from these shares, but no such person holds an interest exceeding 5% of Twist Bioscience’s total outstanding common stock. Subsidiaries through which the position is held are identified in a separate Exhibit 99.